vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $19.1M, roughly 1.6× NewAmsterdam Pharma Co N.V.). NewAmsterdam Pharma Co N.V. runs the higher net margin — -90.7% vs -438.1%, a 347.4% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 220.4%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
DOMH vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $19.1M |
| Net Profit | $-131.8M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -186.1% |
| Net Margin | -438.1% | -90.7% |
| Revenue YoY | 220.4% | 740.1% |
| Net Profit YoY | -12426.2% | 55.5% |
| EPS (diluted) | $-6.94 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | — | ||
| Q3 25 | $50.8M | — | ||
| Q2 25 | $34.1M | $19.1M | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | $9.4M | $12.8M | ||
| Q3 24 | $4.0M | $29.1M | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | — | ||
| Q2 25 | $16.6M | $-17.4M | ||
| Q1 25 | $-32.5M | — | ||
| Q4 24 | $1.1M | $-92.2M | ||
| Q3 24 | $-4.2M | $-16.6M | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $-5.4M | — |
| Q4 25 | -8.9% | — | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | -57.0% | -186.1% | ||
| Q1 25 | -394.6% | — | ||
| Q4 24 | 0.4% | -338.5% | ||
| Q3 24 | -79.1% | -85.9% | ||
| Q2 24 | -44.3% | — | ||
| Q1 24 | -205.2% | — |
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | — | ||
| Q2 25 | 48.7% | -90.7% | ||
| Q1 25 | -400.5% | — | ||
| Q4 24 | 11.4% | -721.7% | ||
| Q3 24 | -104.2% | -57.2% | ||
| Q2 24 | -99.1% | — | ||
| Q1 24 | -398.0% | — |
| Q4 25 | $-6.94 | — | ||
| Q3 25 | $7.27 | — | ||
| Q2 25 | $1.12 | $-0.15 | ||
| Q1 25 | $-3.02 | — | ||
| Q4 24 | $0.21 | $-0.91 | ||
| Q3 24 | $-0.67 | $-0.18 | ||
| Q2 24 | $-1.01 | — | ||
| Q1 24 | $-0.91 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $778.5M |
| Total Assets | $112.9M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | — | ||
| Q3 25 | $176.2M | — | ||
| Q2 25 | $28.2M | $739.2M | ||
| Q1 25 | $18.9M | — | ||
| Q4 24 | $8.2M | $834.2M | ||
| Q3 24 | $7.2M | $422.7M | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $69.4M | — | ||
| Q3 25 | $210.2M | — | ||
| Q2 25 | $88.6M | $778.5M | ||
| Q1 25 | $42.4M | — | ||
| Q4 24 | $39.9M | $757.5M | ||
| Q3 24 | $38.3M | $378.9M | ||
| Q2 24 | $42.4M | — | ||
| Q1 24 | $47.7M | — |
| Q4 25 | $112.9M | — | ||
| Q3 25 | $223.4M | — | ||
| Q2 25 | $109.3M | $815.1M | ||
| Q1 25 | $52.3M | — | ||
| Q4 24 | $47.1M | $864.6M | ||
| Q3 24 | $43.4M | $439.2M | ||
| Q2 24 | $49.1M | — | ||
| Q1 24 | $52.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $-353.0K | $-37.7M | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $-16.7M | $-37.5M | ||
| Q3 24 | $-4.7M | $-12.5M | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $-8.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
NAMS
Segment breakdown not available.
